



Neuberg
DIAGNOSTICS

● India ● UAE ● South Africa ● USA

Neu INSIGHTS



Neuberg
DIAGNOSTICS

CENTER FOR
GENOMIC
MEDICINE



Comprehensive **Oncology**

Serial number : 024 Edition : 1. 2022


OncoCEPT - Solid

(CEPT : Comprehensive Evaluation for Personalized Treatment)

Prominent technical features of OncoCEPT Solid:

- ▶ Enables the detection of variants in 52 key solid tumor genes. These genes are well characterized in the published literature and associated with oncology drugs that are FDA approved, part of National Comprehensive Cancer Network (NCCN) guidelines, or in clinical trials.
- ▶ The assay allows concurrent analysis of DNA and RNA. Simultaneously detects multiple types of variants, including hotspots, single nucleotide variants (SNVs), indels, CNVs, and gene fusions, in a single workflow. Uses formalin-fixed, paraffin embedded (FFPE) tissues, fine-needle aspirates, fresh tissues as starting sample.


Turn around time (TAT): 12 business days.



OncoCEPT - Solid Comprehensive

(CEPT : Comprehensive Evaluation for Personalized Treatment)

OncoCEPT Solid identifies these driver mutations, opens up different targeted therapy options, helps to know about relevant clinical trials, and helps to understanding the prognosis of the patient.




Prominent technical features of OncoCEPT Solid:

- ▶ Enables the detection of variants in 161 key solid tumor genes. These genes are well characterized in the published literature and associated with oncology drugs that are FDA approved, part of National Comprehensive Cancer Network (NCCN) guidelines, or in clinical trials.
- ▶ The assay allows concurrent analysis of DNA and RNA. Simultaneously detect multiple types of variants, including hotspots, single nucleotide variants (SNVs), indels, CNVs, and gene fusions, in a single workflow. Uses formalin-fixed, paraffin embedded (FFPE) tissues, fine-needle aspirates, fresh tissues as starting sample.

Turn around time (TAT): 15 business days.

OncoCEPT - Solid Comprehensive (161)



OncoCEPT - Liquid


(CEPT : Comprehensive Evaluation for Personalized Treatment)

Liquid biopsies are performed on peripheral blood which is easy to access, allowing for more widespread use. Liquid biopsies have drastically revolutionized the field of clinical oncology, offering ease in tumor sampling, continuous monitoring by repeated sampling, devising personalized therapeutic regimens, and screening for therapeutic resistance. Liquid biopsies detect tumor DNA shed from numerous sites within the tumor and thus provide a more comprehensive genomic picture. Liquid biopsies are most commonly used as a complementary technique to standard tissue biopsies.

Prominent technical features of OncoCEPT Solid:

- ▶ Detection of somatic mutations in plasma, down to a level of 0.1% in genes relevant to solid tumors.
- ▶ Analysis of single nucleotide variants, short indels, copy number variations, and fusions that are frequently mutated in research cancer samples.
- ▶ 150 hotspots in 11 genes focused on solid tumors, are analyzed.

Sample type: whole blood.
Turnaround time (TAT): 10 business days.



Inherited Cancer Testing

Multiple

Early onset

Rare



Comprehensive Inherited Cancer Panel (193 genes) ORION Focus

Includes:

- ▶ Common and rare hereditary cancer syndromes
- ▶ All NCCN and ACMG recommended genes

Cancer gene panels:

Breast

Ovarian

Colon

Pancreatic

Thyroid

Endometrial

Prostate

Gastric

Melanoma


Renal

* Single gene testing via NGS available (TP53, PTEN, APC, RB1 etc)

* BRCA 1 and BRCA 2 MLPA available

Patient Support

We offer pre test and post test genetic counseling services by board certified genetic counselors!



Our Specialized Test Panel

Inherited

Cancer Type	Test Name	Test Component	Technique used	Sample requirement	TAT
Hereditary malignancies	ORION focus	193 gene	Next generation Sequencing (NGS)	Whole blood in EDTA (3ml)	28 days

Somatic

Cancer Type	Test Name	Test Component	Technique used	Sample requirement	TAT
Colorectal	Colo Comprehensive	MSI+BRAF+KRAS+NRAS	Next generation Sequencing (NGS)+ PCR	1. Tumor FFPE block containing cancer cells. 2. Whole blood in EDTA (3ml)	15 days
Breast	ER/PR/Her2 by IHC	Immunohistochemistry of ER, PR and Her2	Immunohistochemistry (IHC)	Tumor FFPE block	5 days
	Her2 by FISH	Her2	FISH	Tumor FFPE block	7 days
	Somatic	BRCA1/2	Next generation Sequencing (NGS)	Tumor FFPE block	15 days
	Germline			Whole blood in EDTA (3ml)	28 days
Lung	EGFR by NGS	EGFR (18,19,20,21) exons	Next generation Sequencing (NGS)	Tumor FFPE block	12 days
	OncoCEPT-Solid	52 GENES EGFR, BRAF, KRAS, ERBB2 Rearrangement: ALK, ROS1, NTRK RET, MET etc.	Next generation Sequencing (NGS)	Tumor FFPE block	12 days
	EGFR T790M	EGFR T790 liquid biopsy	Digital PCR	Whole blood in Streck tube (10 ml)	5 days
	OncoCEPT-Liquid	ALK, BRAF, EGFR, ERBB2, KRAS, MAP2K1, MET, NRAS, PIK3CA, ROS1, and TP53	Next generation Sequencing (NGS)	Whole blood in Streck tube (10 ml)	12 days

Cancer Type	Test Name	Test Component	Technique used	Sample requirement	TAT
Thyroid	OncoCEPT Solid	Sequencing: EGFR, BRAF, KRAS, NRAS, HRAS. Fusion: RET-PTC, PAX8-PPAR gamma etc.	Next generation Sequencing (NGS)	Tumor FFPE block	12 days
GIST	OncoCEPT Solid	Sequencing: cKIT, PDGFRA	Next generation Sequencing (NGS)	Tumor FFPE block	12 days
All solid Tumors	OncoCEPT Solid Comprehensive (161 gene panel for all solid tumors)	161 genes	Next generation Sequencing (NGS)	Tumor FFPE block	15 days
HRR Panel	BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L	12 genes etc	Next generation Sequencing (NGS)	Tumor FFPE block	15 days

Our Services



Inherited Genetic Disorder



Reproductive Genetics




Cancer Genomics



Haemato Oncology



Transplant Immunology



Infectious Disorders



Pharmacogenomics



Research Services

PARTNERS IN HEALTH



DR. KUNJAL PATEL

MBBS, DNB (Path.), PDF (TMC)
Molecular Oncopathologist
kunjal.patel@ncgmglobal.com



DR. UDHAYA KOTECHA

M.D. Pediatrics
Head of Division Inherited Disorders (NGS)
Clinical Geneticist
Fellowship in Medical Genetics
udhaya.kotecha@ncgmglobal.com



DR. MEHUL MISTRI

Scientist- Inherited Genetics & Metabolism
PhD Biochemistry
mehul.mistri@ncgmglobal.com



DR. SANDIP SHAH

Consultant Pathologist
M.D. (Pathology & Bacteriology)
Laboratory Director
drsandip@neubergdiagnostics.com

FOR MORE DETAILS, CONTACT US AT



079 61618111

079 40408181

ncgmglobal.com



Neuberg
DIAGNOSTICS

● India ● UAE ● South Africa ● USA